Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹5,554 Cr revenue.
COGS 44.6%, employees 13.0%.
“registered a growth of 30%.”
“Q4 FY26 will be better than Q4 FY25 (461 crores). Expect healthy CDMO growth in FY27”
“with a 26% growth.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 17.5%▲ | 10.5% |
| ROCE | 21.1%▲ | 13.8% |
| Net Margin | 12.4%▲ | 8.7% |
| EBITDA Margin | 26.2%▲ | 16.0% |
| Debt To Equity | 0.45x▲ | 0.21x |
| Rev Growth 3yr | -2.4%▼ | 5.8% |
| EPS Growth 3yr | -23.2%▼ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,722 Cr +21.0% | ₹5,554 Cr +10.2% | ₹5,041 Cr -16.6% | ₹6,041 Cr +22.4% | ₹4,936 Cr +2.5% | ₹4,814 Cr +70.0% | ₹2,832 Cr +23.6% | ₹2,292 Cr |
| Other Income | ₹102 Cr +35.4% | ₹75 Cr +185.1% | ₹26 Cr +339.0% | ₹6 Cr -60.8% | ₹15 Cr -35.3% | ₹24 Cr +299.4% | ₹6 Cr -63.3% | ₹16 Cr |
| Total Income | ₹6,823 Cr +21.2% | ₹5,629 Cr +11.1% | ₹5,067 Cr -16.2% | ₹6,047 Cr +22.1% | ₹4,951 Cr +2.4% | ₹4,837 Cr +70.5% | ₹2,838 Cr +22.9% | ₹2,308 Cr |
| COGS | ₹2,778 Cr +12.1% | ₹2,478 Cr +1.9% | ₹2,432 Cr -12.3% | ₹2,774 Cr +26.5% | ₹2,194 Cr +1.6% | ₹2,158 Cr +52.7% | ₹1,413 Cr +14.4% | ₹1,236 Cr |
| ₹5,691 Cr +10.6% | ₹5,145 Cr +6.5% | ₹4,831 Cr -2.2% | ₹4,938 Cr +27.7% | ₹3,867 Cr +9.4% | ₹3,536 Cr +39.0% | ₹2,544 Cr +16.3% | ₹2,188 Cr | |
| Profit Before Tax | ₹1,133 Cr +133.9% | ₹484 Cr +104.9% | ₹236 Cr -78.7% | ₹1,109 Cr +2.3% | ₹1,084 Cr -16.7% | ₹1,301 Cr +343.1% | ₹294 Cr +145.2% | ₹120 Cr |
| ₹291 Cr +124.1% | ₹130 Cr +90.6% | ₹68 Cr -78.2% | ₹312 Cr +24.2% | ₹251 Cr -20.8% | ₹317 Cr +727.6% | ₹38 Cr +47.5% | ₹26 Cr | |
| Net Profit | ₹841 Cr +134.6% | ₹358 Cr +120.8% | ₹162 Cr -79.5% | ₹793 Cr -4.7% | ₹832 Cr -15.4% | ₹984 Cr +285.4% | ₹255 Cr +172.3% | ₹94 Cr |
| Profit (Owners) | ₹843 Cr +135.4% | ₹358 Cr +123.2% | ₹161 Cr -79.7% | ₹790 Cr -4.5% | ₹828 Cr -15.9% | ₹984 Cr +285.4% | ₹255 Cr +172.3% | ₹94 Cr |
| Minority Interest | (₹3 Cr) ↓ Decline | ₹0.02 Cr -98.8% | ₹2 Cr -48.2% | ₹3 Cr -29.5% | ₹5 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Other Comprehensive Income | (₹10 Cr) -175.3% | (₹4 Cr) -27.2% | (₹3 Cr) +49.0% | (₹6 Cr) ↓ Decline | ₹1 Cr -79.4% | ₹5 Cr ↑ Recovery | (₹11 Cr) -209.7% | (₹4 Cr) |
| EPS | ₹15.62 | ₹6.64 | ₹2.98 | ₹14.67 | ₹15.40 | ₹18.33 | ₹4.78 | ₹1.76 |
| Diluted Shares | ₹54 Cr | ₹54 Cr | ₹54 Cr | ₹54 Cr | ₹54 Cr | ₹54 Cr | ₹53 Cr | ₹53 Cr |
| Profit Or Loss Of Associates | (₹0.99 Cr) ↓ Decline | ₹4 Cr ↑ Recovery | (₹6 Cr) -85.0% | (₹3 Cr) | (₹0.20 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.
Laurus Labs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 02, 2026
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Laurus Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers)...
Laurus Labs Limited has informed the Exchange about Schedule of meet
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication
Laurus Labs Limited has informed the Exchange regarding Change in Director(s) of the company.
Laurus Labs Limited has informed the Exchange about General Updates
Laurus Labs Limited has informed the Exchange about General Updates
Laurus Labs Limited has informed the Exchange regarding Change in Director(s) of the company.
Laurus Labs Limited has informed the Exchange that Record date for the purpose of Dividend is 08-May-2026.
Laurus Labs Limited has informed the Exchange regarding a press release dated April 30, 2026, titled "Press Release for Q4 FY26".